nanoparticles (Fe3O4 NPs) as MRI imaging and CB-TE2A as PET imaging are integrated into a single synthetic molecule in the HER2 positive cancer.Results:One of targeted contrast bimodal imaging probe agents was synthesized and evaluated to target HER2-expressing tumors in a HER2 positive rat ...
Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.Debu Tripathy, MD, professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses fa...
“These preliminary results are consistent with other data previously reported in the HER2-positive metastatic breast and gastric cancer cohorts of this study, demonstrating that further study is warranted for DS-8201 across other HER2-expressing ...
Updated preliminary safety data for this subgroup of trastuzumab-treated HER2-expressing gastric cancer patients were also reported. The most common adverse events (>30 per cent, any grade) included nausea (71.1 per cent), decreased appetite (64.4 per cent), platelet count decreased (33.3 per cen...
In an updated preliminaryanalysis in 31 evaluable patients with other HER2-expressing solid tumors such as colorectal and non-small cell lung cancer, DS-8201 demonstrated a confirmed overall response rate of 38.7 per cent (12/31 patients) and a disease control rate of 83.9 per cent (26/31 pa...
In this phase I study, the safety, pharmacokinetics, and antitumour activity of the HER2-targeted antibody–drug conjugate A166 were evaluated in patients with HER2-expressing advanced solid tumours. Patients with advanced solid tumours refractory to sta
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced so...
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are publishe...
“The findings from the Phase 1 dose-escalation study demonstrate the potential of BDC-1001 to treat patients with HER2-expressing tumors and provide initial clinical validation of ISACs as a therapeutic approach. I look forward to presenting these data and engaging with the medic...
· Heather McKenzie Autoimmune disease Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another March 19, 2025 · 1 min read · Annalee Armstrong Deals Servier Nabs Solid Tumor Asset in up to $780M Deal...